VTGN
VTGN clinical trials: Vistagen Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Vistagen Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 12
- Trials linked
- 11
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
VTGN on the catalyst calendar · VTGN registry changes
- Primary completion Jun 12, 2026ActualPhase 2NCT06809179A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of...VistaGen Therapeutics, Inc. · Social Anxiety DisorderCompletedVTGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 21, 2026ActualPhase 3NCT06615557Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)VistaGen Therapeutics, Inc. · Social Anxiety Disorder (SAD)CompletedVTGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2025ActualPhase 3NCT06358651Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)VistaGen Therapeutics, Inc. · Social Anxiety DisorderCompletedVTGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2022ActualPhase 2NCT04404192PH94B in the Treatment of Adjustment Disorder With AnxietyVistaGen Therapeutics, Inc. · Adjustment Disorder With Anxious MoodCompletedVTGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 16, 2022ActualPhase 3NCT05011396PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2VistaGen Therapeutics, Inc. · Social Anxiety DisorderTerminatedVTGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 23, 2022ActualPhase 3NCT05030350Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)VistaGen Therapeutics, Inc. · Social Anxiety DisorderTerminatedVTGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 22, 2022ActualPhase 3NCT04754802PH94B Nasal Spray for Anxiety Induced by a Public Speaking ChallengeVistaGen Therapeutics, Inc. · Social Anxiety DisorderCompletedVTGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 1, 2022Sponsor estimatePhase 1NCT05280054AV-101 Alone and in Combination With Probenecid in Healthy SubjectsVistaGen Therapeutics, Inc. · Drug Drug InteractionUnknown statusVTGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2023Sponsor estimatePhase 2NCT04147949AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced DyskinesiaVistaGen Therapeutics, Inc. · Parkinson DiseaseUnknown statusVTGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 1, 2019ActualPhase 2NCT03078322AV-101 as Adjunct Antidepressant Therapy in Patients With Major DepressionVistaGen Therapeutics, Inc. · Major Depressive DisorderCompletedVTGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2012ActualPhase 1NCT01483846Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy VolunteersVistaGen Therapeutics, Inc. · Neuropathic PainCompletedVTGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 19, 2019ActualPhase 1/Phase 2NCT03583554Electrophysiological Biomarkers of AV-101Marijn Lijffijt, PhD · HealthyCompletedVTGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner